The influence of Leucine-rich amelogenin peptide on MSC fate by inducing Wnt10b expression

Biomaterials

Volumn 32, Issue 27, 2011, Pages 6478-6486

  Wen, Xin ^a   Cawthorn, William P ^b   MacDougald, Ormond A ^b,c   Stupp, Samuel I ^d,e   Snead, Malcolm L ^a   Zhou, Yan ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adipose tissue engineering; Bone marrow; Cell signaling; ECM (extracellular matrix); Osteogenesis; Stem cell

Indexed keywords

ADIPOSE TISSUE ENGINEERING; BONE MARROW; CELL SIGNALING; ECM (EXTRACELLULAR MATRIX); OSTEOGENESIS;

AMINO ACIDS; BONE; CELL CULTURE; ENAMELS; MAMMALS; PEPTIDES; STEM CELLS; TISSUE; TISSUE ENGINEERING;

SIGNALING;

AMELOGENIN; BETA CATENIN; LEUCINE; WNT10B PROTEIN;

ADIPOGENESIS; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL FATE; CELL TYPE; HEMATOPOIETIC STEM CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADIPOGENESIS; ANIMALS; BETA CATENIN; CELL LINEAGE; DENTAL ENAMEL PROTEINS; GENE KNOCKDOWN TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MESENCHYMAL STEM CELLS; MICE; OSTEOGENESIS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; WNT PROTEINS;

EID: 79960102602     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.05.045     Document Type: Article

References (46)

1. Aldred M.J., Crawford P.J., Roberts E., Thomas N.S. Identification of a nonsense mutation in the amelogenin gene (AMELX) in a family with X-linked amelogenesis imperfecta (AIH1). Hum Genet 1992, 90:413-416.
2. Lagerstrom M., Dahl N., Nakahori Y., Nakagome Y., Backman B., Landegren U., et al. A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). Genomics 1991, 10:971-975.
3. Lagerstrom-Fermer M., Nilsson M., Backman B., Salido E., Shapiro L., Pettersson U., et al. Amelogenin signal peptide mutation: correlation between mutations in the amelogenin gene (AMGX) and manifestations of X-linked amelogenesis imperfecta. Genomics 1995, 26:159-162.
4. Diekwisch T., David S., Bringas P., Santos V., Slavkin H.C. Antisense inhibition of AMEL translation demonstrates supramolecular controls for enamel HAP crystal growth during embryonic mouse molar development. Development 1993, 117:471-482.
5. Lyngstadaas S.P., Risnes S., Sproat B.S., Thrane P.S., Prydz H.P. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. Embo J 1995, 14:5224-5229.
6. Gibson C.W., Yuan Z.A., Hall B., Longenecker G., Chen E., Thyagarajan T., et al. Amelogenin-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem 2001, 276:31871-31875.
7. Hammarstrom L. Enamel matrix, cementum development and regeneration. J Clin Periodontol 1997, 24:658-668.
8. Hammarstrom L. The role of enamel matrix proteins in the development of cementum and periodontal tissues. Ciba Found Symp 1997, 205:246-255. discussion 55-60.
9. Hammarstrom L., Heijl L., Gestrelius S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. J Clin Periodontol 1997, 24:669-677.
10. Gestrelius S., Andersson C., Johansson A.C., Persson E., Brodin A., Rydhag L., et al. Formulation of enamel matrix derivative for surface coating. Kinetics and cell colonization. J Clin Periodontol 1997, 24:678-684.
11. Gestrelius S., Andersson C., Lidstrom D., Hammarstrom L., Somerman M. In vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodontol 1997, 24:685-692.
12. Veis A., Tompkins K., Alvares K., Wei K., Wang L., Wang X.S., et al. Specific amelogenin gene splice products have signaling effects on cells in culture and in implants in vivo. J Biol Chem 2000, 275:41263-41272.
13. Boabaid F., Gibson C.W., Kuehl M.A., Berry J.E., Snead M.L., Nociti F.H., et al. Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. J Periodontol 2004, 75:1126-1136.
14. Lacerda-Pinheiro S., Jegat N., Septier D., Priam F., Bonnefoix M., Bitard J., et al. Early in vivo and in vitro effects of amelogenin gene splice products on pulp cells. Eur J Oral Sci 2006, 114(Suppl. 1):232-238. discussion 54-6, 381-2.
15. Warotayanont R., Zhu D., Snead M.L., Zhou Y. Leucine-rich amelogenin peptide induces osteogenesis in mouse embryonic stem cells. Biochem Biophys Res Commun 2008, 367:1-6.
16. Warotayanont R., Frenkel B., Snead M.L., Zhou Y. Leucine-rich amelogenin peptide induces osteogenesis by activation of the Wnt pathway. Biochem Biophys Res Commun 2009, 387:558-563.
17. Nuttall M.E., Gimble J.M. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004, 4:290-294.
18. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., Nuttall M.E. Playing with bone and fat. J Cell Biochem 2006, 98:251-266.
19. Sottile V., Halleux C., Bassilana F., Keller H., Seuwen K. Stem cell characteristics of human trabecular bone-derived cells. Bone 2002, 30:699-704.
20. Pereira R.C., Delany A.M., Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 2002, 30:685-691.
21. Lecka-Czernik B., Moerman E.J., Grant D.F., Lehmann J.M., Manolagas S.C., Jilka R.L. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376-2384.
22. Park S.R., Oreffo R.O., Triffitt J.T. Interconversion potential of cloned human marrow adipocytes in vitro. Bone 1999, 24:549-554.
23. Bennett C.N., Longo K.A., Wright W.S., Suva L.J., Lane T.F., Hankenson K.D., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 2005, 102:3324-3329.
24. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., Macdougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007, 282:14515-14524.
25. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
26. Bennett C.N., Ross S.E., Longo K.A., Bajnok L., Hemati N., Johnson K.W., et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem 2002, 277:30998-31004.
27. Longo K.A., Wright W.S., Kang S., Gerin I., Chiang S.H., Lucas P.C., et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 2004, 279:35503-35509.
28. Kang S., Bajnok L., Longo K.A., Petersen R.K., Hansen J.B., Kristiansen K., et al. Effects of Wnt signaling on brown adipocyte differentiation and metabolism mediated by PGC-1alpha. Mol Cell Biol 2005, 25:1272-1282.
29. Wright W.S., Longo K.A., Dolinsky V.W., Gerin I., Kang S., Bennett C.N., et al. Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes 2007, 56:295-303.
30. Molenaar M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996, 86:391-399.
31. Finch P.W., He X., Kelley M.J., Uren A., Schaudies R.P., Popescu N.C., et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci U S A 1997, 94:6770-6775.
32. Reya T., O'Riordan M., Okamura R., Devaney E., Willert K., Nusse R., et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000, 13:15-24.
33. Stevens J.R., Miranda-Carboni G.A., Singer M.A., Brugger S.M., Lyons K.M., Lane T.F. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 2010, 25:2138-2147.
34. Haze A., Taylor A.L., Blumenfeld A., Rosenfeld E., Leiser Y., Dafni L., et al. Amelogenin expression in long bone and cartilage cells and in bone marrow progenitor cells. Anat Rec (Hoboken) 2007, 290:455-460.
35. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
36. Ai M., Holmen S.L., Van Hul W., Williams B.O., Warman M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005, 25:4946-4955.
37. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
38. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
39. Christodoulides C., Scarda A., Granzotto M., Milan G., Dalla Nora E., Keogh J., et al. WNT10B mutations in human obesity. Diabetologia 2006, 49:678-684.
40. Guo Y.F., Xiong D.H., Shen H., Zhao L.J., Xiao P., Guo Y., et al. Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet 2006, 43:798-803.
41. Mani A., Radhakrishnan J., Wang H., Mani A., Mani M.A., Nelson-Williams C., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
42. James A.W., Leucht P., Levi B., Carre A.L., Xu Y., Helms J.A., et al. Sonic Hedgehog influences the balance of osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Tissue Eng Part A 2010, 16:2605-2616.
43. Dwyer J.R., Sever N., Carlson M., Nelson S.F., Beachy P.A., Parhami F. Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem 2007, 282:8959-8968.
44. Kim W.K., Meliton V., Amantea C.M., Hahn T.J., Parhami F. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. J Bone Miner Res 2007, 22:1711-1719.
45. Huang Y.C., Tanimoto K., Tanne Y., Kamiya T., Kunimatsu R., Michida M., et al. Effects of human full-length amelogenin on the proliferation of human mesenchymal stem cells derived from bone marrow. Cell Tissue Res 2010, 342:205-212.
46. Tamburstuen M.V., Reppe S., Spahr A., et al. Ameloblastin promotes bone growth by enhancing proliferation of progenitor cells and by stimulating immunoregulators. Eur J Oral Sci 2010, 118:451-459.